Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Mefloquine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 8/20 | 1.00 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.98 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.98 |
| ▸ | AVPR2 known ✓ | P30518 | 1/20 | 0.98 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.98 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.98 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.98 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.98 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.98 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.98 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.98 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.98 |
| ▸ | GHSR known ✓ | Q92847 | 1/20 | 0.98 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.98 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.98 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S,R)-Mefloquine SCHEMBL6818306 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| (S,R)-Mefloquine SCHEMBL41094 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| (R,S)-Mefloquine SCHEMBL5040024 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| Mefloquine SCHEMBL28479869 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| (S,R)-Mefloquine SCHEMBL16702641 | 0.99 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| Mefloquine SCHEMBL8575605 | 0.99 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| Mefloquine SCHEMBL17087807 | 0.99 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| (R,R)-Mefloquine SCHEMBL21781 | 0.99 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| (S,R)-Mefloquine SCHEMBL21780 | 0.99 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 | |
| Mefloquine SCHEMBL7130867 | 0.99 | KCNH2 (1.00) | KCNH2CYP2D6ADORA2AADORA1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2609 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119264107-A | Ionic liquid based on mefloquine and artesunate and preparation of sustained-release suppository thereof | 四川大学 | 2025-01-07 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-115737646-B | Use of Mefloquine Hydrochloride in preparation of anti-enterovirus medicine | 湖北工业大学 | 2024-05-17 | — | — | CN | claimed |
| CN-115267011-B | Liquid chromatography-mass spectrometry chromatography method for qualitative detection of illegally added drugs in oil-control cosmetics | 重庆市食品药品检验检测研究院 | 2024-05-07 | — | — | CN | claimed |
| CN-114136941-B | SARM1 enzyme inhibitor and screening method and application thereof | 北京大学深圳研究生院 | 2024-04-16 | — | — | CN | claimed |
| US-20230346697-A1 | ANTIMICROBIAL AND ANTI-INFLAMMATORY COMPOSITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-02 | — | — | US | claimed |
| CN-114908062-B | Use of mefloquine hydrochloride or mefloquine in preparing medicine for treating coronavirus infectious diseases | 北京化工大学 | 2023-10-20 | — | — | CN | claimed |
| US-20230323485-A1 | METHOD FOR DETERMINING A VIRALLY-INFECTED SUBJECT'S RISK OF DEVELOPING SEVERE SYMPTOMS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-10-12 | — | — | US | claimed |
| WO-2023178169-A2 | COMPOSITIONS AND METHODS FOR TREATING THE PATHOPHYSIOLOGY OF SEVERE VIRAL INFECTION | ANEMOI BIOTECH HOLDINGS, INC. (US) | 2023-09-21 | — | — | WO | claimed |
| EP-4232004-A1 | FRACTAL FORMULATIONS | Nanogyre Sprl (BE) | 2023-08-30 | — | — | EP | claimed |
| WO-2001013907-A2 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF VIRAL INFECTIONS CONTAINING A CALCIUM CHANNEL BLOCKER AND A QUINOLINE | IMMUNE BALANCE TECHNOLOGIES LIMITED COMPANY (US) | 2001-03-01 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| JP-2001500477-A | — | — | 2001-01-16 | — | — | JP | claimed |
| WO-2000072827-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE, INC. (US) | 2000-12-07 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0925308-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | Micrologix Biotech, Inc. (CA) | 1999-06-30 | — | — | EP | claimed |
| CN-1189148-A | 1, 3-propane diol derivatives as bioactive compounds | SCOTIA HOLDINGS PLC (GB) | 1998-07-29 | — | — | CN | claimed |
| CN-1187813-A | Fatty acid esters as bioactive compounds | SCOTIA HOLDINGS PLC (GB) | 1998-07-15 | — | — | CN | claimed |
| WO-1998007745-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | MICROLOGIX BIOTECH, INC. (CA) | 1998-02-26 | — | — | WO | claimed |
| EP-0137375-B1 | MEFLOQUINIC HYDROCHLORIDE | F. HOFFMANN-LA ROCHE AG (CH) | 1990-08-08 | — | — | EP | claimed |